molecules of the month


oral selective ER degrader and antagonist

in Ph. IIb studies for ER+ breast cancer

from ligand-based design and opt.

J. Med. Chem., Sep. 29, 2020

AstraZeneca, Cambridge, UK / Waltham, MA

Structure of AZD9833, a selective oestrogen receptor degrader (SERD)
1 min read

AZD9833 is a potent, orally available selective estrogen receptor degrader (SERD) and antagonist in development for breast cancer. The only approved SERD is the widely used fulvestrant, which is given by monthly intramuscular injection and may have submaximal antitumor activity. A safe, oral alternative has been highly sought after and the oncology community looks forward to clinical efficacy data from the AZD team.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: